Vitexin / MAPK Cancer Research Results

VT, Vitexin: Click to Expand ⟱
Features:

Vitexin - Apigenin-8-C-Glucoside

Alternative Names: Apigenin-8-C-glucoside, apigenin-8-C-β-D-glucopyranoside

Type: Flavone C-glycoside / apigenin derivative

Function: Vitexin is a naturally occurring C-glycosylated flavone in which glucose is attached to apigenin at the C-8 position. It exhibits antioxidant, anti-inflammatory, metabolic, cardiovascular, neuroprotective, and antiproliferative activities and can modulate pathways involving NF-κB, Nrf2/HO-1, MAPK, PI3K/AKT, AMPK, HIF-1α, apoptosis, and oxidative stress.

-see also IsoVitexin

Cancer: Preclinical studies indicate antiproliferative, pro-apoptotic, anti-migratory, anti-invasive, and anti-inflammatory effects across multiple cancer models. Reported mechanisms include modulation of PI3K/AKT, MAPK, NF-κB, HIF-1α, ROS, apoptosis, and cell-cycle signaling. Clinical anticancer efficacy has not been established.

Alzheimer's Disease: Preclinical evidence suggests neuroprotective activity through antioxidant and anti-inflammatory effects, reduction of neuronal injury, regulation of oxidative stress and mitochondrial function, and modulation of signaling pathways relevant to cognitive impairment and amyloid-associated neurotoxicity. Clinical efficacy for Alzheimer's disease has not been established.



MAPK, mitogen-activated protein kinase: Click to Expand ⟱
Source: CGL-CS
Type:
Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death).

MAPK Pathways: The MAPK family includes several pathways, the most notable being:
1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival.
2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis.
3.p38 MAPK: Associated with inflammatory responses and apoptosis.

Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations.
Altered Expression Levels:
Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival.
Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling.
The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers.

Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion.


Scientific Papers found: Click to Expand⟱
7896- IVT,  VT,    Molecular targets of vitexin and isovitexin in cancer therapy: a critical review
- Review, Var, NA
chemoPv↑, Dose↝, ACE/ACE1↓, Ca+2↓, *iNOS↓, *COX2/PTGS2↓, *ROS↓, *Stroke↓, Apoptosis↑, MMP↓, Bcl-2↓, Casp3↑, Casp9↑, TumAuto↑, HSP90↑, ER Stress↑, Hif1a↓, TumMeta↓, angioG↓, Tf↓, MAPK↓, PI3K↓, Akt↓, β-catenin/ZEB1↓, TumCCA↑, FOXO3↓, mTOR↓,
7887- VT,  IVT,    Dietary Flavonoids Vitexin and Isovitexin: New Insights into Their Functional Roles in Human Health and Disease Prevention
- Review, AD, NA - Review, Var, NA
*antiOx↑, *Inflam↓, *AntiCan↑, *Bacteria↓, *neuroP↑, *Obesity↓, *cardioP↑, *ROS↓, *MMP↑, *ATP↑, *MFN2↑, *DRP1/DNM1L↓, *FOXO3↑, *NRF2↑, *Ferroptosis↓, *GPx4↑, TumCP↓, HMGB1↓, PI3K↓, Akt↓, Hif1a↓, CDK1↓, CycB/CCNB1↓, TumCCA↑, Apoptosis↑, P53↑, NF-kB↓, ERK↓, p‑PI3K↓, miR-34a↑, Apoptosis↑, CSCs?, *MAPK↓, *HO-1↑, *hepatoP↑, *AMPK↑, *Akt↑, *GSK‐3β↑, *chemoP↑, *Casp3↓, *IRes↝, *GlucoseCon↑, ChemoSen↑, *GSH↑, *SOD↑, *ATF2↑, *GPx↑, *GSTs↑, *AntiAge↑, *Stroke↓, *AChE↓, *ACE/ACE1↓, *ACE2↓, *GutMicro↑, *MPO↓, *H+/K+-ATPase↓, *AntiDiabetic↑, *GLUT4↑, *Obesity↓, *HH↓, *RenoP↑, *BioAv↓, *BioAv↝, *BioAv↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0)

ACE/ACE1↓, 1,  

Metal & Cofactor Biology(tgid=2)

Tf↓, 1,  

Mitochondria & Bioenergetics(tgid=3)

MMP↓, 1,  

Cell Death(tgid=5)

Akt↓, 2,   Apoptosis↑, 3,   Bcl-2↓, 1,   Casp3↑, 1,   Casp9↑, 1,   MAPK↓, 1,  

Protein Folding & ER Stress(tgid=8)

ER Stress↑, 1,   HSP90↑, 1,  

Autophagy & Lysosomes(tgid=9)

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10)

P53↑, 1,  

Cell Cycle & Senescence(tgid=11)

CDK1↓, 1,   CycB/CCNB1↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12)

CSCs?, 1,   ERK↓, 1,   FOXO3↓, 1,   miR-34a↑, 1,   mTOR↓, 1,   PI3K↓, 2,   p‑PI3K↓, 1,  

Migration(tgid=13)

Ca+2↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14)

angioG↓, 1,   Hif1a↓, 2,  

Immune & Inflammatory Signaling(tgid=16)

HMGB1↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21)

ChemoSen↑, 1,   Dose↝, 1,  

Functional Outcomes(tgid=23)

chemoPv↑, 1,  
Total Targets: 34

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0)

ACE/ACE1↓, 1,   ACE2↓, 1,   H+/K+-ATPase↓, 1,   IRes↝, 1,   Stroke↓, 2,  

Redox & Oxidative Stress(tgid=1)

antiOx↑, 1,   Ferroptosis↓, 1,   GPx↑, 1,   GPx4↑, 1,   GSH↑, 1,   GSTs↑, 1,   HO-1↑, 1,   MFN2↑, 1,   MPO↓, 1,   NRF2↑, 1,   ROS↓, 2,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3)

ATP↑, 1,   DRP1/DNM1L↓, 1,   MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4)

AMPK↑, 1,   GlucoseCon↑, 1,  

Cell Death(tgid=5)

Akt↑, 1,   ATF2↑, 1,   Casp3↓, 1,   Ferroptosis↓, 1,   iNOS↓, 1,   MAPK↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

FOXO3↑, 1,   GSK‐3β↑, 1,   HH↓, 1,  

Barriers & Transport(tgid=15)

GLUT4↑, 1,  

Immune & Inflammatory Signaling(tgid=16)

COX2/PTGS2↓, 1,   Inflam↓, 1,  

Synaptic & Neurotransmission(tgid=18)

AChE↓, 1,  

Drug Metabolism & Resistance(tgid=21)

BioAv↓, 1,   BioAv↑, 1,   BioAv↝, 1,  

Clinical Biomarkers(tgid=22)

GutMicro↑, 1,  

Functional Outcomes(tgid=23)

AntiAge↑, 1,   AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   Obesity↓, 2,   RenoP↑, 1,  

Infection & Microbiome(tgid=24)

Bacteria↓, 1,  
Total Targets: 49

Scientific Paper Hit Count for: MAPK, mitogen-activated protein kinase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:462  Target#:181  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page